Australian immuno-oncology company Imugene has dosed the first Australian subject in a Phase Ib trial of its allogeneic CAR T ...

An Investigational New Drug (IND) is a drug or biological drug that has not been approved for general use by the FDA. It is used in a clinical trial to investigate its safety and efficacy. The term ...

The biotech sector witnessed a see-saw performance in 2024. While the year started on a positive note, much of the gains ...

The "bio-bucks" deal gives the company up to $20 million in upfront and research payouts initially. From the San Francisco ...

(RTTNews) - Olema Pharmaceuticals (OLMA) announced the FDA has cleared Investigational New Drug application for OP-3136, a small molecule that potently and selectively inhibits KAT6, a validated ...

FP008 is a proprietary and patented drug candidate using Fapon Biopharma's cutting-edge antibody technology. As a first-in-class biologic, FP008 uniquely combines an engineered IL-10 monomer (IL-10M) ...

today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for OP-3136, a novel small molecule that potently and selectively ...

PH-762 is a potential non-surgical treatment for skin cancers. The on-going Phase 1b trial (NCT# 06014086) received FDA clearance for an Investigational New Drug Application to evaluate PH-762 in the ...

Neurizon has filed an Investigational New Drug application with the US FDA for lead drug candidate NUZ-001 to treat ...

Aging-focused drug-development company BioAge Labs Inc. signed a potential $530 million, multi-year research collaboration ...

Detailed price information for Olema Pharmaceuticals Inc (OLMA-Q) from The Globe and Mail including charting and trades.